Mary King, PA
Physician Assistant · Centennial, CONPI 1245728203
Payments from drug & device makers
Across 275 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst US Sales Co., LLC$733
- ADMA Biomanufacturing LLC$557
- Takeda Pharmaceuticals U.S.A., Inc.$515
- CSL Behring$511
- Pharming Healthcare, Inc.$354
- Sanofi$316
- plus $3K from 30 others
What the payments were for
- Consulting fees$2103%
- Food & beverage$5,63494%
- Education$1813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst US Sales Co., LLC | 57 | $733 |
| ADMA Biomanufacturing LLC | 5 | $557 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $515 |
| CSL Behring | 17 | $511 |
| Pharming Healthcare, Inc. | 14 | $354 |
| Sanofi | 16 | $316 |
| ANI Pharmaceuticals, Inc. | 3 | $312 |
| Genentech USA, Inc. | 13 | $263 |
| Cycle Pharmaceuticals Inc | 12 | $260 |
| GSK | 20 | $259 |
| Catalyst Pharmaceuticals, Inc. | 12 | $246 |
| AstraZeneca | 9 | $217 |
| Novartis | 9 | $182 |
| Regeneron Healthcare Solutions, Inc. | 7 | $166 |
| Grifols USA, LLC | 7 | $162 |
| AbbVie | 7 | $134 |
| Bio Products Laboratory USA, Inc. | 8 | $131 |
| Nestle Healthcare Nutrition Inc. | 5 | $85 |
| Kaleo, Inc. | 4 | $73 |
| UCB, Inc. | 3 | $71 |
| Paratek Pharmaceuticals, Inc. | 3 | $61 |
| GC Biopharma USA, Inc. | 3 | $49 |
| Incyte Corporation | 2 | $46 |
| Amgen | 2 | $42 |
| Octapharma USA, Inc. | 2 | $42 |
| Sobi, Inc | 1 | $38 |
| Lundbeck LLC | 1 | $34 |
| Biocryst Pharmaceuticals, Inc. | 1 | $30 |
| Eisai Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Organon | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| X4 Pharmaceuticals, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Ionis Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,026 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RuconestC1 Esterase Inhibitor, Recomb | 42 | $3,593,778 |
| FirazyrIcatibant Acetate | 25 | $1,107,285 |
| OrladeyoBerotralstat Hydrochloride | 16 | $658,876 |
| HaegardaC1 Esterase Inhibitor | 24 | $581,031 |
| Dupixent SyringeDupilumab | 25 | $95,847 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,739 |
| Hydroxychloroquine Sulfate | 29 | $1,038 |
| Montelukast Sodium | 23 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharming Healthcare, Inc.Ruconest | $354 | $3,593,77842 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Firazyr | $515 | $1,107,28525 claims |
| Biocryst US Sales Co., LLCOrladeyo | $733 | $658,87616 claims |
| CSL BehringHaegarda | $511 | $581,03124 claims |
| GSKTrelegy Ellipta | $259 | $7,73912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.
Other physician assistant in Centennial
- Hillary ChingCentennial$35K
- Rachelle WebsterCentennial$18K
- Yury GadayevCentennial$18K
- Melissa ButlerCentennial$12K
- Jordan BeckerCentennial$10K
- Donald MooreEnglewood$246K
- Neekan AeiniGreenwood Village$234K
- Korby HowellCortez$182K
- Heather FinlaysonLittleton$180K
- Kristen LervikDenver$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.